IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0234996.html
   My bibliography  Save this article

Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia

Author

Listed:
  • Huajie Jin
  • Paul Tappenden
  • Stewart Robinson
  • Evanthia Achilla
  • David Aceituno
  • Sarah Byford

Abstract

Background: Numerous economic models have assessed the cost-effectiveness of antipsychotic medications in schizophrenia. It is important to understand what key impacts of antipsychotic medications were considered in the existing models and limitations of existing models in order to inform the development of future models. Objectives: This systematic review aims to identify which clinical benefits, clinical harms, costs and cost savings of antipsychotic medication have been considered by existing models, to assess quality of existing models and to suggest good practice recommendations for future economic models of antipsychotic medications. Methods: An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo, Cochrane database of systematic reviews, The NHS Economic Evaluation Database and Health Technology Assessment database) to identify economic models of schizophrenia published between 2005–2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Key impacts of antipsychotic medications considered by exiting models were descriptively summarised. Results: Sixty models were included. Existing models varied greatly in key impacts of antipsychotic medication included in the model, especially in clinical outcomes used for assessing reduction in psychotic symptoms and types of adverse events considered in the model. Quality of existing models was generally low due to failure to capture the health and cost impact of adverse events of antipsychotic medications and input data not obtained from best available source. Good practices for modelling antipsychotic medications are suggested. Discussions: This review highlights inconsistency in key impacts considered by different models, and limitations of the existing models. Recommendations on future research are provided.

Suggested Citation

  • Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & David Aceituno & Sarah Byford, 2020. "Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
  • Handle: RePEc:plo:pone00:0234996
    DOI: 10.1371/journal.pone.0234996
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0234996
    Download Restriction: no

    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0234996&type=printable
    Download Restriction: no

    File URL: https://libkey.io/10.1371/journal.pone.0234996?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 367-372, June.
    2. Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther, 2006. "A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(3), pages 165-172, September.
    3. Martin J. Buxton & Michael F. Drummond & Ben A. Van Hout & Richard L. Prince & Trevor A. Sheldon & Thomas Szucs & Muriel Vray, 1997. "Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life," Health Economics, John Wiley & Sons, Ltd., vol. 6(3), pages 217-227, May.
    4. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.
    5. Andrew H. Briggs & Ron Goeree & Gord Blackhouse & Bernie J. O’Brien, 2002. "Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease," Medical Decision Making, , vol. 22(4), pages 290-308, August.
    6. David Moher & Alessandro Liberati & Jennifer Tetzlaff & Douglas G Altman & The PRISMA Group, 2009. "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement," PLOS Medicine, Public Library of Science, vol. 6(7), pages 1-6, July.
    7. S Robinson, 2008. "Conceptual modelling for simulation Part I: definition and requirements," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 59(3), pages 278-290, March.
    8. Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & James H. MacCabe & David Aceituno & Sarah Byford, 2020. "A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway," PharmacoEconomics, Springer, vol. 38(6), pages 537-555, June.
    9. Solomon Lubinga & Byamah Mutamba & Angelo Nganizi & Joseph Babigumira, 2015. "A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda," Applied Health Economics and Health Policy, Springer, vol. 13(5), pages 493-506, October.
    10. Bernie O'Brien & Jose Luis Viramontes, 1994. "Willingness to Pay," Medical Decision Making, , vol. 14(3), pages 289-297, August.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Huajie Jin & Stewart Robinson & Wenru Shang & Evanthia Achilla & David Aceituno & Sarah Byford, 2021. "Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies," PharmacoEconomics, Springer, vol. 39(7), pages 757-770, July.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    2. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    3. Boshen Jiao & Anirban Basu & Joshua Roth & M. Bender & Ilsa Rovira & Traci Clemons & Dalyna Quach & Scott Ramsey & Beth Devine, 2021. "The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature," PharmacoEconomics, Springer, vol. 39(11), pages 1225-1241, November.
    4. Holger Möller & Fiona Haigh & Rema Hayek & Lennert Veerman, 2020. "What Is the Best Practice Method for Quantifying the Health and Economic Benefits of Active Transport?," IJERPH, MDPI, vol. 17(17), pages 1-16, August.
    5. S. Rajsic & H. Gothe & H. H. Borba & G. Sroczynski & J. Vujicic & T. Toell & Uwe Siebert, 2019. "Economic burden of stroke: a systematic review on post-stroke care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 107-134, February.
    6. Finkelstein, Eric A. & Bilger, Marcel & Baid, Drishti, 2019. "Effectiveness and cost-effectiveness of incentives as a tool for prevention of non-communicable diseases: A systematic review," Social Science & Medicine, Elsevier, vol. 232(C), pages 340-350.
    7. Jason Madan & Meghan Bruce Kumar & Miriam Taegtmeyer & Edwine Barasa & Swaran Preet Singh, 2020. "SEEP-CI: A Structured Economic Evaluation Process for Complex Health System Interventions," IJERPH, MDPI, vol. 17(18), pages 1-12, September.
    8. Darcy M. Anderson & Ryan Cronk & Donald Fejfar & Emily Pak & Michelle Cawley & Jamie Bartram, 2021. "Safe Healthcare Facilities: A Systematic Review on the Costs of Establishing and Maintaining Environmental Health in Facilities in Low- and Middle-Income Countries," IJERPH, MDPI, vol. 18(2), pages 1-22, January.
    9. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    10. Alexander V van Schoonhoven & Judith J Gout-Zwart & Marijke J S de Vries & Antoinette D I van Asselt & Evgeni Dvortsin & Pepijn Vemer & Job F M van Boven & Maarten J Postma, 2019. "Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-22, September.
    11. Joan Mendivil & Marilena Appierto & Susana Aceituno & Mercè Comas & Montserrat Rué, 2019. "Economic evaluations of screening strategies for the early detection of colorectal cancer in the average-risk population: A systematic literature review," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-18, December.
    12. Nikita M. John & Stuart J. Wright & Sean P. Gavan & Caroline M. Vass, 2019. "The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1123-1131, November.
    13. Christian Kromer & Daniel Celis & Diana Sonntag & Wiebke K Peitsch, 2018. "Biologicals and small molecules in psoriasis: A systematic review of economic evaluations," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-22, January.
    14. Chiranjeev Sanyal & Paul Stolee & Don Juzwishin & Don Husereau, 2018. "Economic evaluations of eHealth technologies: A systematic review," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-11, June.
    15. Habibollah Arefian & Monique Vogel & Anja Kwetkat & Michael Hartmann, 2016. "Economic Evaluation of Interventions for Prevention of Hospital Acquired Infections: A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-15, January.
    16. Brigid M Gillespie & Claudia Bull & Rachel Walker & Frances Lin & Shelley Roberts & Wendy Chaboyer, 2018. "Quality appraisal of clinical guidelines for surgical site infection prevention: A systematic review," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-17, September.
    17. Stephen Mac & Sara R da Silva & Beate Sander, 2019. "The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-17, January.
    18. Wolf Rogowski & Wolfram Elsner, 2021. "How economics can help mitigate climate change - a critical review and conceptual analysis of economic paradigms," Bremen Papers on Economics & Innovation 2106, University of Bremen, Faculty of Business Studies and Economics.
    19. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    20. Zartashia Ghani & Johan Jarl & Johan Sanmartin Berglund & Martin Andersson & Peter Anderberg, 2020. "The Cost-Effectiveness of Mobile Health (mHealth) Interventions for Older Adults: Systematic Review," IJERPH, MDPI, vol. 17(15), pages 1-13, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0234996. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.